<DOC>
	<DOCNO>NCT00907933</DOCNO>
	<brief_summary>This First Time Human ( FTIH ) study investigate safety , tolerability pharmacokinetics ( PK ) ) single , escalate b ) twice-daily 14 day repeat dose intranasal SB-705498 healthy volunteer ( HVT ) . The safety tolerability single intranasal 498 dosing assess establish initiate evaluation repeat intranasal 498 dosing .</brief_summary>
	<brief_title>Intranasal SB-705498 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Healthy , determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female 18 60 year age inclusive . A female subject eligible participate : Nonchildbearing potential define female document tubal occlusion , bilateral salpingectomy , bilateral oophorectomy hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous FSH &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method protocol wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential agrees use one contraception method list protocol . Female subject willing participate study must agree use contraception screen visit 15 day postlast treatment administration . Male subject must agree use one contraception method list protocol . For male subject willing participate study criterion must follow time screen visit 15 day postlast treatment administration . Nonsmoker least 6 month pack history le equal 5 pack year ( Pack year = ( No . cigarettes smoked/day/20 ) x No . year smoke ) . Body weight great equal 50 kg body mass index ( BMI ) within range 19 29.9 kg/m2 ( inclusive ) . Normal assessment vital sign 12lead ECG screening . A subject may include study abnormality deem clinically significant Investigator . Capable give write informed consent , include compliance requirement restriction list consent form . Available complete require study measurement . Past medical history rhinitis , include allergic , nonallergic rhinitis rhinosinusitis . Subjects recent upper respiratory tract infection ( URTIs ) allow study nasal symptom completely resolve 3 week prior screen . Nasal condition likely affect outcome study , i.e . nasal septal perforation , nasal polyp , nasal malformation . History frequent nosebleed . A history gastrointestinal , hepatic , renal condition know interfere absorption , distribution , metabolism excretion drug . History regular alcohol consumption within 6 month study define : average weekly intake great 21 unit average daily intake great 3 unit ( male ) , defined average weekly intake great 14 unit average daily intake great 2 unit ( female ) . One unit equivalent halfpint ( 220mL ) beer 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine . Positive prestudy drug/alcohol/smoking screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids , benzodiazepine methadone . Positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test human immunodeficiency virus ( HIV ) antibody . Exposure four new chemical entity within 6 month prior start study . Participation clinical trial new molecule entity clinical trial within 3 month start study . Use prescription nonprescription drug , well vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History drug allergy , opinion Investigator GSK Medical Monitor , contraindicate participation study . Donation blood blood product excess 500mL within 56 day period prior start study . Pregnant female determine positive serum urine betahuman chorionic gonadatrophin ( betahCG ) test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>